Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 92.73% | 6,798.46% | 15,189.21% | 12,385.07% | 12,969.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.73% | 6,798.46% | 15,189.21% | 12,385.07% | 12,969.75% |
| Cost of Revenue | 80.64% | 585.04% | 943.37% | 817.58% | 1,430.15% |
| Gross Profit | 1,354.96% | 93.63% | 824.98% | 583.91% | 85.54% |
| SG&A Expenses | -4.72% | 39.92% | 42.14% | 46.69% | 80.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.60% | 44.00% | 31.65% | 24.23% | 20.57% |
| Operating Income | -11.64% | -2.97% | 28.60% | 24.75% | 7.42% |
| Income Before Tax | -11.27% | -3.16% | 34.82% | 26.04% | 7.89% |
| Income Tax Expenses | 236.35% | -30.54% | 188.57% | -22.28% | -205.66% |
| Earnings from Continuing Operations | -14.99% | -2.82% | 32.50% | 26.56% | 8.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.99% | -2.82% | 32.50% | 26.56% | 8.85% |
| EBIT | -11.64% | -2.97% | 28.60% | 24.75% | 7.42% |
| EBITDA | -12.06% | -2.65% | 31.77% | 27.76% | 11.19% |
| EPS Basic | 2.08% | 15.22% | 43.33% | 40.47% | 28.17% |
| Normalized Basic EPS | 5.27% | 15.11% | 44.14% | 40.05% | 27.39% |
| EPS Diluted | 2.08% | 15.22% | 43.33% | 40.47% | 28.17% |
| Normalized Diluted EPS | 5.27% | 15.11% | 44.14% | 40.05% | 27.39% |
| Average Basic Shares Outstanding | 17.45% | 21.28% | 19.12% | 23.37% | 26.88% |
| Average Diluted Shares Outstanding | 17.45% | 21.28% | 19.12% | 23.37% | 26.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |